Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

• Published in: Breast cancer research : BCR Vol. 11; no. 1; p. R12
• Main Authors: Nakayama, Satoshi, Torikoshi, Yasuhiro, Takahashi, Takeshi, Yoshida, Tomokazu, Sudo, Tamotsu, Matsushima, Tomoko, Kawasaki, Yuko, Katayama, Aya, Gohda, Keigo, Hortobagyi, Gabriel N, Noguchi, Shinzaburo, Sakai, Toshiyuki, Ishihara, Hideki, Ueno, Naoto T
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.01.2009; National Library of Medicine - MEDLINE Abstracts; BioMed Central
• Subjects: Animals; Antineoplastic Agents, Phytogenic - pharmacology; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - enzymology; Breast Neoplasms - pathology; CDC2 Protein Kinase - metabolism; Cell Cycle - drug effects; Chromatin - metabolism; Cyclin-Dependent Kinase 2 - metabolism; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Dosage and administration; Drug Resistance, Neoplasm; Drug therapy; Female; Genetic aspects; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Paclitaxel - pharmacology; Physiological aspects; Protein kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; United States; Japan

Paclitaxel is used widely in the treatment of breast cancer. Not all tumors respond to this drug, however, and the characteristics that distinguish resistant tumors from sensitive tumors are not well defined. Activation of the spindle assembly checkpoint is required for paclitaxel-induced cell death...